Stay updated on CLL1-CD33 cCAR in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the CLL1-CD33 cCAR in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CLL1-CD33 cCAR in Hematologic Malignancies Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:50:18.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase I interventional treatment study evaluating the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high-risk hematologic malignancies.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:11.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes examples of criteria such as a person's general health condition or prior treatments.
    Difference
    12%
    Check dated 2024-05-22T21:11:33.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:18.000Z thumbnail image

Stay in the know with updates to CLL1-CD33 cCAR in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CLL1-CD33 cCAR in Hematologic Malignancies Clinical Trial page.